

# **'Better research for better health'** *A holistic approach to challenges & opportunities*

# Charlemagne building, rue de la Loi, 170, 1040 Brussels, Belgium

Thursday, 21<sup>st</sup> January 2016

## DRAFT PROGRAMME

09.00 - 09.30	Registration and welcome coffee
09.30 - 09.45	Keynote speech: Addressing challenges in EU health research- the Scientific Panel for Health
	<b>Carlos Moedas,</b> EU Commissioner for Research, Science and Innovation, European Commission
09.45 - 10.00	<b>Strengthening European biomedical and health research for better health -</b> Introduction & Key messages from SPH vision paper
	<b>Karin Sipido</b> , Professor of Cardiology, KU Leuven; President, Alliance for Biomedical Research in Europe; SPH Chair
10.00 - 11.30	Session 1: Cross-border research: collaboration in Europe and beyond
	<ul> <li>Aim of session: To discuss the opportunities and highlight barriers for cross- border research within and beyond Europe.</li> <li>Moderators: Stephen Holgate &amp; Maciej Banach, SPH Members Speakers:</li> <li>Breaking down the barriers: the example of the Cancer Core Europe- Ulrik Ringborg, Senior Professor in Oncology, Karolinska Institute</li> <li>Cross-border collaboration in infectious disease- Nedret Emiroglu, Deputy Director, Division of Communicable Diseases, Health Security and Environment, World Health Organisation</li> <li>Global public health and prevention programmes- Valentin Fuster, General Director, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Madrid, Spain</li> </ul>

*Discussion (panel & public):* **How to sustainably support cross-border collaboration?** 

- The European Commission: Ruxandra Draghia-Akli, Director, Directorate for Health, DG Research and Innovation, European Commission
- *Member State funding organisations' initiatives:* Stig Slordahl, CEO, The Central Norway Regional Health Authority
- **Research Institutes:** Iain Mattaj, Director General, European Molecular Biology Laboratory (EMBL)

#### **Q&A** session

11.30 - 11.45	Coffee break
11.45 – 13.00	Session 2: Cross-border research: academia, innovation and health care
	<i>Aim of session</i> : To discuss challenges and opportunities in multidisciplinary / mixed model collaborations
	Moderators: Ruxandra Draghia-Akli, Director, Directorate for Health, DG

Research and Innovation, European Commission & Michael Manns, SPH Member

Speakers:

- Breaking down borders between public and private research- Elias Zerhouni, President, Global Research and Development, Sanofi-aventis Group (TBC)
- *Health technology research alliances* Andrzej Rys, Director, Health Systems and products, DG Health and Food safety, European Commission (TBC)
- **Research within the health care system- Dame Sally Davies**, Chief Medical Officer, United Kingdom (TBC)

#### 12.15 – 13.00 *Discussion (panel & public):* Fostering multidisciplinary and mixed models

- European Institute of Technology (EIT) Health & Academia- Helen Ward, Director of Education for the School of Public Health, Imperial College, United Kingdom; Interim Director EIT-Health UK-Ireland
- *SME's and Academia* Helga Ruebsamen-Schaeff, Chair, Scientific Advisory Board, AiCuris GMBh & Co. KG & SPH member

## • Industry and Academia- Speaker TBD

#### **Q&A** session

13.00 - 14.00	Networking lunch
14.00 - 15.15	Session 3: The regulatory framework as a facilitating environment for innovation
	<i>Aim of the session</i> : To discuss specific regulations in the process from target discovery to patient, focusing on the path to market approval and new technologies.
	<i>Moderators:</i> <b>Bente M. Stalknecht</b> & <b>Laurent Degos</b> , SPH Members Speakers:
	• How to ensure excellent clinical research- Speaker TBD
	<ul> <li>Innovative treatments- Hans-Georg Eichler, Chief Medical Officer, European Medicines Agency (EMA) (TBC)</li> <li>Enabling and disruptive technologies – Paul Timmers, Director, Digital Society, Trust &amp; Security, DG Connect European Commission (TBC)</li> </ul>
14.30 - 15.15	Discussion (panel & public): <b>Implementation of regulations as facilitators and</b> not barriers
	• <b>Clinical Trial co-ordination- Francoise Meunier</b> , Director General, European Organisation for Research and Treatment of Cancer (EORTC)
	• Technology in health care and patient interaction: Speaker TBD
	The industry view- Speaker TBD

#### **Q&A** session

15.15 - 15.30	Coffee break
15.30 – 17.00	Session 4: A comprehensive biomedical research policy - value-based, health- centred and science-led
	Aim of the session: To discuss the different actors and their role as stakeholders

in guiding research policy – The current state of play and future expectations

*Moderators:* Frank Luyten & Martin Buxton, SPH Members *Speakers:* 

- Who sets the research agenda? Speaker TBD
- *Patient expectations for and participation in research-* Anders Olauson, President, European Patients' Forum (EPF) (TBC)
- Big projects and Darwinian principles for successful science- Francis Collins, Director, National Institutes of Health (NIH) (TBC)

## 16.00 – 17.00 *Discussion (panel & public):* Sharing perspectives and expectations

- Juleen Zierath, Professor, Department of Molecular Medicine and Surgery, Karolinska Institute (TBC)
- Patrick Bauerle, Chief Scientific Officer, Micromet Inc. (TBC)
- **Rudi Balling**, Director, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

### Q&A session

17.00 - 17.30	Closing of conference & final words
	<b>Aim of the session:</b> To present ideas for the future that would capture the concepts of the previous sessions: how to ensure a research policy and vision that is value-based, health- and people-centred, and science-led?
	<i>A need for action &amp; a vision for the future</i> <b>Detlev Ganten</b> , President, World Health Summit & SPH Member
	<b>The SPH as a driver – final words and next steps</b> <b>Karin Sipido</b> , Professor of Cardiology, KU Leuven; President, Alliance for Biomedical Research in Europe; SPH Chair
17.30 - 18.30	Networking reception